W Zhao1, J Lin2. 1. Department of Cell Biology, Wuxi Medical College, Jiangnan University, Wuxi 214122, China. 2. Department of Neurosurgery, First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Abstract
OBJECTIVE: To investigate neuregulin 2 (NRG2) expression in gliomas and its role in glioma development. METHODS: We compared the expression levels of NRG2 and glial fibrillary acidic protein (GFAP) in low-grade glioma (LGG) and glioblastoma multiforme (GBM) with those in normal control samples using GEPIA database.The correlation between NRG2 and GFAP expression and their association with the overall survival of patients with LGG and GBM were analyzed.Immunohistochemical staining was used to detect NRG2 protein expression levels in a tissue microarray consisting of human gliomas of different grades, and potential co-localization of NRG2 and GFAP was analyzed using a double-labeling immunofluorescence assay.Western blotting was used to investigate the effect of perifosine (an AKT inhibitor) on the regulation of GFAP expression by NRG2 in human glioblastoma U-87 MG cells. RESULTS: Both LGG and GBM tissues, especially the former, exhibited high expressions of NRG2 (P < 0.01).In GBM samples, patients with low NRG2 levels had slightly higher overall survival after 30 months than patients with high NRG2 levels.The expression level of NRG2 mRNA was negatively correlated with that of GFAP in LGG samples (P < 0.01) but positively correlated with GFAP expression in GBM samples (P < 0.01).Immunofluorescence assay showed that NRG2 and GFAP were co-expressed in the same tumor cells of LGG tissues but were separately expressed in different tumor cells in GBM tissues.In U-87 MG cells, treatment with recombinant human NRG2 obviously promoted the expression of GFAP, and this effect was significantly inhibited by perifosine (P < 0.01). CONCLUSION: NRG2 is highly expressed in gliomas of different grades and regulates GFAP expression in glioma cells at least partly via the Akt signaling pathway to affect the survival of glioma patients.
OBJECTIVE: To investigate neuregulin 2 (NRG2) expression in gliomas and its role in glioma development. METHODS: We compared the expression levels of NRG2 and glial fibrillary acidic protein (GFAP) in low-grade glioma (LGG) and glioblastoma multiforme (GBM) with those in normal control samples using GEPIA database.The correlation between NRG2 and GFAP expression and their association with the overall survival of patients with LGG and GBM were analyzed.Immunohistochemical staining was used to detect NRG2 protein expression levels in a tissue microarray consisting of human gliomas of different grades, and potential co-localization of NRG2 and GFAP was analyzed using a double-labeling immunofluorescence assay.Western blotting was used to investigate the effect of perifosine (an AKT inhibitor) on the regulation of GFAP expression by NRG2 in human glioblastoma U-87 MG cells. RESULTS: Both LGG and GBM tissues, especially the former, exhibited high expressions of NRG2 (P < 0.01).In GBM samples, patients with low NRG2 levels had slightly higher overall survival after 30 months than patients with high NRG2 levels.The expression level of NRG2 mRNA was negatively correlated with that of GFAP in LGG samples (P < 0.01) but positively correlated with GFAP expression in GBM samples (P < 0.01).Immunofluorescence assay showed that NRG2 and GFAP were co-expressed in the same tumor cells of LGG tissues but were separately expressed in different tumor cells in GBM tissues.In U-87 MG cells, treatment with recombinant human NRG2 obviously promoted the expression of GFAP, and this effect was significantly inhibited by perifosine (P < 0.01). CONCLUSION: NRG2 is highly expressed in gliomas of different grades and regulates GFAP expression in glioma cells at least partly via the Akt signaling pathway to affect the survival of glioma patients.
Authors: Catherine Marshall; Edith Blackburn; Mellissa Clark; Steven Humphreys; William J Gullick Journal: Breast Cancer Res Treat Date: 2005-10-27 Impact factor: 4.872
Authors: Sith Sathornsumetee; David A Reardon; Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Jeremy N Rich Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Feng Yin; Jian Ning Zhang; Shu Wei Wang; Chun Hui Zhou; Ming Ming Zhao; Wen Hong Fan; Ming Fan; Shuang Liu Journal: PLoS One Date: 2015-01-05 Impact factor: 3.240
Authors: J Laskin; S V Liu; K Tolba; C Heining; R F Schlenk; P Cheema; J Cadranel; M R Jones; A Drilon; A Cseh; S Gyorffy; F Solca; M Duruisseaux Journal: Ann Oncol Date: 2020-09-09 Impact factor: 51.769